Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Gene therapy could be used as an agent to protect normal tissues, including the esophagus and lung, from damage during a second administration of radiation therapy for non-small cell lung cancer, according to an animal study presented by University of Pittsburgh researchers at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.
The nation's leading cancer organizations report that Americans' risk of dying from cancer continues to decline and that the rate of new cancers is holding steady. The "Annual Report to the Nation on the Status of Cancer, 1975-2002," published in the Oct. 5, 2005, issue of the Journal of the National Cancer Institute, shows observed cancer death rates from all cancers combined dropped 1.1 percent per year from 1993 to 2002.
The tyrosine kinase inhibitor erlotinib (Tarceva) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston.
While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced disease - cancer confined to the lungs - finding the right combination of drugs - and the best timing of treatment - has been tricky.
Chemotherapy is standard treatment for patients with advanced non-small cell lung cancer, although benefits are modest and toxicity substantial. Massimo Di Maio and colleagues hypothesised that neutropenia, a haematological toxicity, could be a predictor of drug activity and treatment efficacy.
Lorus Therapeutics has announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program.
A preoperative testing strategy combining two procedures may help improve the accuracy of determining the stage of lung cancer, according to an article in the August 24/31 issue of JAMA: The Journal of the American Medical Association.
Two designer cancer drugs differed dramatically in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer cells, reports a team headed by scientists at the Dana-Farber Cancer Institute.
Introgen Therapeutics has announced that a patent with broad claims directed to combination therapy with the p53 gene and conventional chemotherapy or radiation was issued in China.
By the time the human genome was mapped, cancer researchers had already begun investigating the proteins that were encoded by these newly identified genes.
An international clinical study led by Canadian researchers has demonstrated that a drug called erlotinib increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options.
Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.
A Canadian national clinical trial has found that chemotherapy following surgery for early-stage non-small cell lung cancer significantly improves survival for the disease over just surgery alone.
Recent research which has shown that chemotherapy can significantly lengthen life in many patients with lung cancer, has meant that doctors, for the first time in decades, have begun making major changes in the treatment of the disease.
AstraZeneca has announced that after discussions with the U.S. Food and Drug Administration (FDA), the company is making a labeling change to Iressa (gefitinib tablets).
Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).
Patients whose lung cancer has spread to the lymph nodes have a better chance of long-term survival if they receive combined modality therapy, such as concurrent radiation and chemotherapy followed by surgery, according to a study that Loyola University Health System’s Dr. Kathy S. Albain presented at the American Society of Clinical Oncology annual meeting.
Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).
Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).
Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.